CCT2 and age-related macular degeneration: While CCT2 expression varied significantly between intermediate and advanced AMD stages, no significant changes were observed between any stage with normal samples, indicating that CCT2 upregulation may be more relevant to advanced-stage disease processes rather than serving as an early biomarker.